DARPA Awards $11.3M to UC San Diego for Engineered Red Blood Cells

UC San Diego has secured an $11.3 million contract from DARPA to engineer 'smart' red blood cells that temporarily boost oxygen delivery and physical endurance. The three-year project, led by Dr. Alejandro Chavez, uses gene editing to create cells that respond to exertion, with potential future applications in treating cancer and vascular diseases.
Key points
- UC San Diego’s School of Medicine received up to $11.312 million from the Defense Advanced Research Projects Agency (DARPA) for a three-year research initiative.
- The project aims to engineer red blood cells that detect physical exertion and produce proteins to enhance oxygen delivery to tissues, thereby improving soldier endurance.
- Principal investigator Dr. Alejandro Chavez and co-investigator Dr. Hojun Li will collaborate with teams from Northeastern University, the University of Pennsylvania, and MIT.
- Researchers will utilize gene-editing techniques and test the cells in hollow-fiber bioreactors, avoiding human trials during this initial phase.
- While the primary goal is military performance enhancement, the technology may eventually treat conditions like anemia, heart attacks, strokes, and cancer.
Background
This development aligns with a broader trend in biomedical research focusing on cellular engineering and regenerative medicine. Recent advancements in tissue engineering, such as efforts to regrow teeth using stem cells, highlight the growing potential of manipulating biological structures for specific functions. Additionally, the focus on blood health connects to ongoing medical challenges regarding blood disorders, such as aplastic anemia, where understanding blood cell function is critical for treatment and survival.
How outlets are covering it
The California Post emphasizes the military context, linking the project to Defense Secretary Pete Hegseth’s recent focus on fitness and physical readiness. In contrast, Newswise presents the story as a high-risk, high-reward scientific endeavor, highlighting the 'moonshot' nature of DARPA funding. While the California Post notes the potential for treating medical conditions like diabetic skin ulcers, Newswise and the researchers themselves stress the broader implications for cancer detection and treatment, suggesting the technology’s value extends far beyond its initial military application.
Why it matters
This project represents a significant step in the field of red blood cell engineering, potentially revolutionizing how the human body responds to physical stress. Success could lead to breakthroughs in treating oxygen-deprivation diseases and improving athletic performance, while also advancing the understanding of cancer detection at microscopic levels. The collaboration between top-tier universities and defense agencies underscores the dual-use potential of advanced biomedical technologies.
What to watch
The research team will proceed with developing and optimizing the engineered cells in bioreactors over the next three years. Following the successful completion of this phase, the focus may shift toward exploring clinical applications for treating various medical conditions, including cancer and vascular diseases, though no human trials are planned for this initial contract period.
Want the full story? Read the original reporting
Read on New York Post